<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJO</journal-id>
<journal-title-group>
<journal-title>International Journal of Oncology</journal-title></journal-title-group>
<issn pub-type="ppub">1019-6439</issn>
<issn pub-type="epub">1791-2423</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ijo.2014.2379</article-id>
<article-id pub-id-type="publisher-id">ijo-44-06-1933</article-id>
<article-categories>
<subj-group>
<subject>Article</subject></subj-group></article-categories>
<title-group>
<article-title><italic>In vitro</italic> and <italic>in vivo</italic> effects of a nutrient mixture on breast cancer progression</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>ROOMI</surname><given-names>M.W.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>KALINOVSKY</surname><given-names>T.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>ROOMI</surname><given-names>N.M.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>CHA</surname><given-names>J.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>RATH</surname><given-names>M.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>NIEDZWIECKI</surname><given-names>A.</given-names></name><xref ref-type="corresp" rid="c1-ijo-44-06-1933"/></contrib>
<aff id="af1-ijo-44-06-1933">Dr. Rath Research Institute, Santa Clara, CA 95050, 
<country>USA</country></aff></contrib-group>
<author-notes>
<corresp id="c1-ijo-44-06-1933">Correspondence to: Dr Aleksandra Niedzwiecki, Dr. Rath Research Institute, 1260 Memorex Drive, Santa Clara, CA 95050, USA, E-mail: <email>author@drrath.com</email></corresp></author-notes>
<pub-date pub-type="collection">
<month>06</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>04</month>
<year>2014</year></pub-date>
<volume>44</volume>
<issue>6</issue>
<fpage>1933</fpage>
<lpage>1944</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>01</month>
<year>2014</year></date>
<date date-type="accepted">
<day>17</day>
<month>03</month>
<year>2014</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Long-term survival of patients with breast cancer remains poor, due to metastasis and recurrence. We investigated the effects of a novel nutrient mixture (NM) containing ascorbic acid, lysine, proline and green tea extract <italic>in vitro</italic> and <italic>in vivo</italic> on 4T1 murine breast cancer, a representative model for metastatic breast cancer. After one week of isolation, 5&#x02013;6-week-old female Balb/C mice were inoculated with 5&#x000D7;10<sup>5</sup> 4T1 cells into the mammary pad and randomly divided into two groups; the control group was fed a regular diet and the NM group a regular diet supplemented with 0.5&#x00025; NM. After four weeks, the mice were sacrificed and their tumors, lungs, livers, kidneys, hearts and spleens were excised and processed for histology. Dimensions (length and width) of tumors were measured using a digital caliper, and the tumor burden was calculated using the following formula: 0.5 &#x000D7; length &#x000D7; width. We also tested the effect of NM <italic>in vitro</italic> on 4T1 cells, measuring cell proliferation by MTT assay, MMP secretion by zymography, invasion through Matrigel, migration by scratch test and morphology by H&#x00026;E staining. NM inhibited tumor weight and burden of 4T1 tumors by 50&#x00025; (p&#x0003D;0.02) and 53.4&#x00025; (p&#x02264;0.0001), respectively. Lung metastasis was profoundly inhibited by NM supplementation: mean number of colonies was reduced by 87&#x00025; (p&#x0003C;0.0001) and mean weight of lungs by 60&#x00025; (p&#x0003D;0.0001) compared to control mice. Metastasis to liver, spleen, kidney and heart was significantly reduced with NM supplementation. <italic>In vitro</italic>, NM exhibited 50&#x00025; toxicity over the control at 250 and 500 <italic>&#x003BC;</italic>g/ml concentrations. Zymography demonstrated MMP-2 and MMP-9 secretion which was inhibited by NM in a dose-dependent manner, with virtual total inhibition of both at 1,000 <italic>&#x003BC;</italic>g/ml. Migration by scratch test and invasion through Matrigel were inhibited in a dose-dependent manner with total block of invasion at 250 and of migration at 1,000 <italic>&#x003BC;</italic>g/ml. These results suggest that NM has therapeutic potential in the treatment of breast cancer.</p></abstract>
<kwd-group>
<kwd>breast cancer 4T1 cell line</kwd>
<kwd>nutrients</kwd>
<kwd>tumor growth</kwd>
<kwd>metastasis</kwd>
<kwd>MMPs</kwd>
<kwd>migration</kwd>
<kwd>Matrigel invasion</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Breast cancer, the most prevalent cancer in women worldwide and the leading cause of cancer death in women, was projected to claim the lives of &#x0223C;39,620 women in the USA in 2013 (<xref rid="b1-ijo-44-06-1933" ref-type="bibr">1</xref>). Though treatable in early stages, once metastasis has occurred, the survival rate is drastically reduced to a median of 2&#x02013;3 years and treatment focuses on palliative care (<xref rid="b2-ijo-44-06-1933" ref-type="bibr">2</xref>).</p>
<p>Critical events in tumor cell invasion include cell attachment, proteolytic degradation of the extracellular matrix (ECM) and migration through the disrupted matrix (<xref rid="b3-ijo-44-06-1933" ref-type="bibr">3</xref>). Rath and Pauling (<xref rid="b4-ijo-44-06-1933" ref-type="bibr">4</xref>) proposed that nutrients such as lysine and ascorbic acid could act as natural inhibitors of ECM degradation, inhibiting MMP activity and strengthening the connective tissue surrounding cancer cells, and thus potentially modulating tumor growth and expansion. We have developed strategies to inhibit cancer development and its spread using naturally occurring nutrients such as lysine, proline, ascorbic acid and green tea extract (NM). This nutrient mixture has exhibited synergistic anticancer activity <italic>in vivo</italic> and <italic>in vitro</italic> in a number of cancer cell lines through inhibition of cancer cell growth, MMP secretion, invasion, metastasis and angiogenesis (<xref rid="b5-ijo-44-06-1933" ref-type="bibr">5</xref>).</p>
<p>A major problem in studying metastasis has been the lack of suitable models that faithfully represent the metastatic process as it occurs <italic>in vivo</italic>. While some human xenograft models can approximate primary tumor growth in mice, replication of tumor metastasis is more problematic (<xref rid="b6-ijo-44-06-1933" ref-type="bibr">6</xref>&#x02013;<xref rid="b8-ijo-44-06-1933" ref-type="bibr">8</xref>). Generally, human tumor cells metastasize poorly in mice and metastases are associated with unexpected characteristics. In contrast, murine tumor cell models often metastasize more effectively and display metastatic characteristics more similar to those observed in cancer patients (<xref rid="b9-ijo-44-06-1933" ref-type="bibr">9</xref>). Since microenvironments and tumor-host interactions play important roles in tumor cell behavior, this is not surprising. When introduced orthoptopically, 4T1 is capable of metastasis to several organs affected in breast cancer, including lungs, liver and brain as well as bone.</p>
<p>In this study, our main objective was to determine the effect of dietary supplementation with NM on the development of tumors and metastasis to other organs challenging mice with breast cancer 4T1 cells into the mammary pad. The 4T1 mammary carcinoma model was chosen as it has several characteristics that make it a suitable experimental animal model for human mammary cancer growth and metastasis (<xref rid="b10-ijo-44-06-1933" ref-type="bibr">10</xref>,<xref rid="b11-ijo-44-06-1933" ref-type="bibr">11</xref>). The tumor cells are easily transplanted into the mammary gland so that the primary tumor grows in the anatomically correct site and, as in human breast cancer, 4T1 metastatic disease develops spontaneously from the primary tumor. In addition, metastatic spread of 4T1 metastases to other organs and the draining lymph nodes is similar to that of human mammary cancer (<xref rid="b10-ijo-44-06-1933" ref-type="bibr">10</xref>). In addition, we studied the effect of NM on 4T1 cells <italic>in vitro</italic> evaluating viability, MMP secretion, migration and invasion.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cancer cell line and culture</title>
<p>Murine breast cancer cell line 4T1 was obtained from ATCC (American Type Culture Collection, Rockville, MD, USA). 4T1 cells were maintained in DMEM, supplemented with 10&#x00025; fetal bovine serum, 100 U/ml penicillin and 100 <italic>&#x003BC;</italic>g/ml streptomycin. The media and sera used were obtained from ATCC, and antibiotics (penicillin and streptomycin) were from Gibco BRL (Long Island, NY, USA).</p></sec>
<sec>
<title>Composition of the nutrient mixture</title>
<p>The nutrient mixture (NM) was composed of the following in the ratio indicated: vitamin C (as ascorbic acid and as Mg, Ca and palmitate ascorbate) 700 mg; L-lysine 1,000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract &#x0005B;derived from green tea leaves, was obtained from US Pharma Lab; the certificate of analysis indicated the following characteristics: total polyphenol 80&#x00025;, catechins 60&#x00025;, epigallocatechin gallate (EGCG) 35&#x00025; and caffeine 1.0&#x00025;&#x0005D;; 1,000 mg; selenium 30 <italic>&#x003BC;</italic>g; copper 2 mg; manganese 1 mg.</p></sec></sec>
<sec>
<title>In vivo studies</title>
<sec>
<title>Animals</title>
<p>Female Balb/C mice, approximately five weeks of age on arrival, were purchased from Simonsen Laboratories (Gilroy, CA, USA) and maintained in microisolator cages under pathogen-free conditions on a 12-h light/12-h dark schedule for a week. All procedures were performed according to humane and customary care and use of experimental animals and followed a protocol approved by internal institutional animal safety review committee.</p></sec>
<sec>
<title>Experimental design</title>
<p>After housing for a week, the mice (n&#x0003D;14) were inoculated with 5&#x000D7;10<sup>5</sup> 4T1 cells in 0.2 ml PBS and 0.1 ml Matrigel (BD Bioscience, Bedford, MA, USA) into the mammary pad. After injection, the mice were randomly divided into two groups and maintained for four weeks on the following diets; the control group mice were fed regular Purina mouse chow and the NM group the regular diet supplemented with 0.5&#x00025; NM (w/w). During the study, the mice consumed, on the average, 4 g of their respective diets per day. Thus, the supplemented mice received &#x0223C;20 mg of NM per day. After four weeks, the mice were sacrificed and their tumors, lungs, livers, kidneys, hearts and spleens were excised and processed for histology. Dimensions (length and width) of tumors were measured using a digital caliper, and the tumor burden was calculated using the following formula: 0.5 &#x000D7; length &#x000D7; width. Mean weight of mice at initiation of study and termination of study did not differ significantly between the groups.</p></sec>
<sec>
<title>Histology</title>
<p>Tissue samples were fixed in 10&#x00025; buffered formalin and sent to IDEXX Reference Laboratories for processing, blocking, sectioning and staining with hematoxylin and eosin (H&#x00026;E). Tumors and organs from mice were evaluated using a standard light microscope.</p></sec></sec>
<sec>
<title>In vitro studies</title>
<sec>
<title>Cell culture</title>
<p>Murine breast 4T1 cells were grown in DMEM, supplemented with 10&#x00025; fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml) in 24-well tissue culture plates (Costar, Cambridge, MA, USA). Cells were incubated with 1 ml of media at 37&#x000B0;C in a tissue culture incubator equilibrated with 95&#x00025; air and 5&#x00025; CO<sub>2</sub>. At near confluence, the cells were treated with the nutrient mixture, dissolved in media and tested at 0, 10, 50, 100, 500 and 1,000 <italic>&#x003BC;</italic>g/ml in triplicate at each dose. Phorbol 12-myristate 13-acetate (PMA), 100 ng/ml, was added to cells to induce MMP-9 secretion. The plates were then returned to the incubator.</p></sec>
<sec>
<title>MTT assay</title>
<p>Cell viability was evaluated by MTT assay, a colorimetric assay based on the ability of viable cells to reduce a soluble yellow tetrazolium salt &#x0005B;3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide&#x0005D; (MTT) to a blue formazan crystal by mitochondrial succinate dehydrogenase activity of viable cells. This test is a good index of mitochondrial activity and thus of cell viability. After 24-h incubation, the cells were washed with phosphate-buffered saline (PBS) and 500 <italic>&#x003BC;</italic>l of MTT (Sigma no. M-2128) 0.5 mg/ml in media was added to each well. After MTT addition (0.5 mg/ml) the plates were covered and returned to the 37&#x000B0;C incubator for 2 h, the optimal time for formazan product formation. Following incubation, the supernatant was carefully removed from the wells, the formazan product was dissolved in 1 ml DMSO and absorbance was measured at 570 nm in Bio Spec 1601, Shimadzu spectrometer. The OD<sub>570</sub> of the DMSO solution in each well was considered to be proportional to the number of cells. The OD<sub>570</sub> of the control (treatment without supplement) was considered 100&#x00025;.</p></sec>
<sec>
<title>Gelatinase zymography</title>
<p>Gelatinase zymography was performed in 10&#x00025; Novex Pre-Cast SDS polyacrylamide gel (Invitrogen Corp.) in the presence of 0.1&#x00025; gelatin under non-reducing conditions. Culture media (20 <italic>&#x003BC;</italic>l) were mixed with sample buffer and loaded for SDS-PAGE with tris glycine SDS buffer, as suggested by the manufacturer (Novex). Samples were not boiled before electrophoresis. Following electrophoresis the gels were washed twice in 2.5&#x00025; Triton X-100 for 30 min at room temperature to remove SDS. The gels were then incubated at 37&#x000B0;C overnight in substrate buffer containing 50 mM Tris-HCl and 10 mM CaCl<sub>2</sub> at pH 8.0 and stained with 0.5&#x00025; Coomassie Blue R250 in 50&#x00025; methanol and 10&#x00025; glacial acetic acid for 30 min and destained. Upon renaturation of the enzyme, the gelatinases digested the gelatin in the gel, producing clear bands against an intensely stained background. Protein standards were run concurrently and approximate molecular weights were determined by plotting the relative mobilities of known proteins.</p></sec>
<sec>
<title>Migration: scratch test</title>
<p>To study cell migration, a 2-mm wide single uninterrupted scratch was made from top to bottom of culture plates of cancer cells grown to confluence. Culture plates were washed with PBS and incubated with NM in medium and tested at 0, 50, 100, 250, 500 and 1,000 <italic>&#x003BC;</italic>g/ml in triplicate at each dose for 24 h. Cells were washed with PBS, fixed and stained with H&#x00026;E and photomicrographs were taken.</p></sec>
<sec>
<title>Matrigel invasion</title>
<p>Invasion studies were conducted using Matrigel (Becton-Dickinson) inserts in 24-well plates. Suspended in medium, 4T1 cells were supplemented with nutrients, as specified in the design of the experiment, and seeded on the insert in the well. Thus both the medium on the insert and in the well contained the same supplements. The plates with the inserts were then incubated in a culture incubator equilibrated with 95&#x00025; air and 5&#x00025; CO<sub>2</sub> for 24 h. After incubation, the media from the wells were withdrawn. The cells on the upper surface of the inserts were gently scrubbed away with cotton swabs. The cells that had penetrated the Matrigel membrane and migrated onto the lower surface of the Matrigel were stained with hematoxylin and eosin and visually counted under a microscope.</p></sec>
<sec>
<title>Morphology</title>
<p>Morphology of cells cultured for 24 h in test concentrations of NM were evaluated by H&#x00026;E staining and observed and photographed by microscopy.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>The results are expressed as means &#x000B1; SD, as indicated in the results, for the groups. Data was analyzed by independent sample &#x02018;t&#x02019;-test.</p></sec></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>In vivo studies</title>
<sec>
<title>Tumor weight and burden</title>
<p>NM strongly inhibited tumor growth and burden of 4T1 tumors in female Balb/C mice. Mean tumor weight was inhibited by 50&#x00025; (p&#x0003D;0.02) with NM 0.5&#x00025; dietary supplementation, as shown in <xref rid="f1-ijo-44-06-1933" ref-type="fig">Fig. 1A</xref> and tumor burden was inhibited by 53.4&#x00025; (p&#x02264;0.0001), as shown in <xref rid="f1-ijo-44-06-1933" ref-type="fig">Fig. 1B</xref>. Mean tumor weight of supplemented mice was 0.91&#x000B1;0.43 g and that of mice on the control diet 1.83&#x000B1;0.81 g. Mean tumor burden of supplemented mice was 140&#x000B1;48 cm<sup>2</sup> and that of mice on the control diet 300&#x000B1;45 cm<sup>2</sup>. Images of mice and gross tumors from groups are shown in <xref rid="f2-ijo-44-06-1933" ref-type="fig">Fig. 2</xref>.</p></sec>
<sec>
<title>Tumor histopathology</title>
<p>Histologically, both groups demonstrated irregularly round subcutaneous tumors with large central areas of tumor necrosis involving 70&#x00025; of the tumor mass in the control mice and 50&#x02013;70&#x00025; in the supplemented mice. Viable, peripheral tumor tissue consisted of sheaths of small irregularly-round to spindle-shaped cells with poorly defined cytoplasm and often vesiculated nuclei. Mitotic figures averaged 1&#x02013;2 per high-power field (<xref rid="f3-ijo-44-06-1933" ref-type="fig">Fig. 3</xref>).</p></sec>
<sec>
<title>Metastasis to lungs</title>
<p>Mice supplemented with NM 0.5&#x00025; showed profoundly reduced number of colonies in the lungs as contrasted to the lungs of control mice. Mean number of colonies in the lungs of supplemented mice (9&#x000B1;8.4) were 13&#x00025; (p&#x0003C;0.0001) of the mean number of colonies in the lungs of control mice (69&#x000B1;15.6), as shown in <xref rid="f4-ijo-44-06-1933" ref-type="fig">Fig. 4A</xref>. Furthermore, mean weight of lungs of supplemented mice (0.24&#x000B1;0.05 g) were 40.7&#x00025; (p&#x0003D;0.0001) of the mean weight of lungs of control mice (0.59&#x000B1;0.16 g), as shown in <xref rid="f4-ijo-44-06-1933" ref-type="fig">Fig. 4B</xref>. Images of gross lungs from groups are shown in <xref rid="f5-ijo-44-06-1933" ref-type="fig">Fig. 5</xref>.</p></sec>
<sec>
<title>Lung histopathology</title>
<p>Multiple metastases were observed in the lungs of control mice in contrast to few, small metastatic lesions in lungs of NM supplemented mice. Neoplastic cells were large, irregularly round, with prominent large, irregularly round nuclei and scant cytoplasm (<xref rid="f6-ijo-44-06-1933" ref-type="fig">Fig. 6</xref>).</p></sec>
<sec>
<title>Mean weights of livers, kidneys, spleens and hearts</title>
<p>No significant differences were found between control and NM supplemented mean organ weights, as shown in <xref rid="f7-ijo-44-06-1933" ref-type="fig">Fig. 7</xref>.</p></sec>
<sec>
<title>Metastasis to liver</title>
<p>Two of three liver sections examined from control group livers showed 2&#x02013;3 small, metastatic lesions associated with severe, perivascular and sinusoidal neutrophilic infiltration. The third section had no evidence of metastasis or severe neutrophilic infiltration, but did have multifocal areas of severe, acute liver necrosis. All four sections of liver examined in NM 0.5&#x00025; fed mice, showed no definite metastatic lesions. Many vessels were severely cuffed with neutrophils. A few questionable cells presented in sinusoids, but these most likely were myeloid in origin. Gross images of control livers are shown in <xref rid="f8-ijo-44-06-1933" ref-type="fig">Fig. 8</xref> and histopathology of livers from control and supplemented mice is shown in <xref rid="f9-ijo-44-06-1933" ref-type="fig">Fig. 9</xref>.</p></sec>
<sec>
<title>Metastasis to kidney</title>
<p>Three partial kidney sections of control mice presented subscapsular, metastatic lesions and one section areas of acute infarction. Of three sections of NM kidney examined, no metastases or specific changes were noted. Gross images of control kidneys are shown in <xref rid="f10-ijo-44-06-1933" ref-type="fig">Fig. 10</xref> and histopathology of kidneys from control and supplemented mice is shown in <xref rid="f11-ijo-44-06-1933" ref-type="fig">Fig. 11</xref>.</p></sec>
<sec>
<title>Metastasis to heart</title>
<p>Among the control group heart sections examined, four of five showed myocardial metastatic lesions, one large and three smaller metastases. In the NM heart sections examined, two of four sections each had a metastatic lesion near the base of the heart. Gross images of hearts from both groups are shown in <xref rid="f12-ijo-44-06-1933" ref-type="fig">Fig. 12</xref> and histopathology of hearts from control and supplemented mice is shown in <xref rid="f13-ijo-44-06-1933" ref-type="fig">Fig. 13</xref>.</p></sec>
<sec>
<title>Metastasis to spleen</title>
<p>Of the three sections of control group spleens examined, all showed severe, extramedullary hematopoiesis and 2&#x02013;3 small metastases. Sections of NM spleen showed severe, extramedullary hematopoietic activity and a small, metastatic lesion in one section. Gross images of control spleens are shown in <xref rid="f14-ijo-44-06-1933" ref-type="fig">Fig. 14</xref> and histopathology of spleens from control and supplemented mice is shown in <xref rid="f15-ijo-44-06-1933" ref-type="fig">Fig. 15</xref>.</p></sec></sec>
<sec>
<title>In vitro</title>
<sec>
<title>Cell proliferation: MTT assay</title>
<p>NM exhibited dose-dependent inhibition of 4T1 cell growth with 50&#x00025; (p&#x0003C;0.0001) antiproliferative effect at 250 and 500 <italic>&#x003BC;</italic>g/ml and 60&#x00025; (p&#x0003C;0.0001) at 1,000 <italic>&#x003BC;</italic>g/ml compared to control, as shown in <xref rid="f16-ijo-44-06-1933" ref-type="fig">Fig. 16</xref>.</p></sec>
<sec>
<title>Gelatinase zymography</title>
<p>Zymography demonstrated MMP-2 and MMP-9 secretion by untreated and PMA-treated 4T1 cells. NM inhibited secretion of both MMPs in a dose-dependent manner with virtual total inhibition of both at 1,000 <italic>&#x003BC;</italic>g/ml, as shown in <xref rid="f17-ijo-44-06-1933" ref-type="fig">Fig. 17</xref>.</p></sec>
<sec>
<title>Migration: scratch test</title>
<p>NM reduced breast cancer 4T1 cell migration in a dose-dependent manner, with total inhibition at 1,000 <italic>&#x003BC;</italic>g/ml, as shown in <xref rid="f18-ijo-44-06-1933" ref-type="fig">Fig. 18</xref>.</p></sec>
<sec>
<title>Matrigel invasion</title>
<p>NM significantly inhibited 4T1 invasion through Matrigel in a dose-dependent manner, with total block at 250 <italic>&#x003BC;</italic>g/ml, as shown in <xref rid="f19-ijo-44-06-1933" ref-type="fig">Fig. 19</xref>.</p></sec>
<sec>
<title>Morphology: H&#x00026;E staining</title>
<p>H&#x00026;E staining showed no morphological changes even at higher concentrations of NM, as shown in <xref rid="f20-ijo-44-06-1933" ref-type="fig">Fig. 20</xref>.</p></sec></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The results of the <italic>in vivo</italic> study of murine 4T1 cells injected into the mammary pads of Balb/C mice demonstrated significant suppression of tumor growth (50&#x00025; reduction in tumor weight and 53&#x00025; in tumor burden) with NM dietary supplementation. Lung metastasis was profoundly inhibited by NM supplementation: mean number of colonies was reduced by 87&#x00025; and mean weight of lungs by 60&#x00025; compared to control mice. Metastasis to liver, spleen, kidney and heart was significantly reduced with NM supplementation. The results from the <italic>in vitro</italic> studies support the <italic>in vivo</italic> findings. <italic>In vitro</italic>, NM inhibited cell proliferation by 50&#x00025; at 250 and 500 <italic>&#x003BC;</italic>g/ml concentrations compared to the control. Zymography demonstrated MMP-2 and MMP-9 secretion which was inhibited by NM in a dose-dependent manner, with virtual total inhibition of both at 1,000 <italic>&#x003BC;</italic>g/ml. Migration by scratch test and invasion through Matrigel were inhibited dose-dependently with total block of invasion at 250 and of migration at 1,000 <italic>&#x003BC;</italic>g/ml.</p>
<p>Tao <italic>et al</italic> reported that metastasis of 4T1 tumors was associated with extensive necrosis and inflammation within the primary tumor and hematopoiesis in several mouse organs including spleen and liver (<xref rid="b10-ijo-44-06-1933" ref-type="bibr">10</xref>). In our study, both groups demonstrated irregularly round subcutaneous tumors with large central areas of tumor necrosis involving 70&#x00025; of the tumor mass in the control mice and 50&#x02013;70&#x00025; in the supplemented mice. As discussed earlier, we observed multiple metastases in the lungs of control mice in contrast to few small metastatic lesions in lungs of NM supplemented mice. Splenic metastasis showed severe, extramedullary hematopoiesis and 2&#x02013;3 small metastases in the spleen sections of control mice and a small metastatic lesion and extramedullary hematopoietic activity in the sections of supplemented mice. Liver metastasis in our study showed several small metastatic lesions associated with severe, perivascular and sinusoidal neutrophilic infiltration in the control sections and absence of metastatic lesions but presence of neutrophils in supplemented sections.</p>
<p>Bonfil <italic>et al</italic> reported that the distribution of necrosis within a primary tumor was responsible in part for the development of metastases (<xref rid="b12-ijo-44-06-1933" ref-type="bibr">12</xref>), and that tumor necrosis was an important source of gelatinase/type IV collagenase, mainly in its 92-kDa form, and thus played a major role in tumor invasion (<xref rid="b13-ijo-44-06-1933" ref-type="bibr">13</xref>). In a previous study, we found that among gulo KO mice injected with mammary 4T1 cells, those mice deprived of ascorbate developed large tumors with dark cores, showing more necrosis, and poorly defined borders, while gulo KO mice supplemented with ascorbate hosted smaller tumors with smaller, lighter cores, less necrosis and enhanced collagen encapsulation, signifying less metastatic potential (<xref rid="b14-ijo-44-06-1933" ref-type="bibr">14</xref>).</p>
<p>High MMP-2 and MMP-9 levels have been found to correlate with aggressiveness of cancers, as exemplified by breast cancer (<xref rid="b15-ijo-44-06-1933" ref-type="bibr">15</xref>,<xref rid="b16-ijo-44-06-1933" ref-type="bibr">16</xref>). Our present <italic>in vitro</italic> study showed dose-dependent inhibition of MMP-2 and MMP-9 secretion, cell migration and cell invasion through Matrigel with treatment of 4T1 cells with NM.</p>
<p>A causal relationship between inflammation and 4T1 metastasis was proposed by Connolly <italic>et al</italic> based on observation of an inhibitory effect of the COX-2 inhibitor sC-236 on metastasis of 4T1 after primary tumor excision (<xref rid="b17-ijo-44-06-1933" ref-type="bibr">17</xref>). Inflammation has been noted to have a positive effect on metastasis in several systems (<xref rid="b18-ijo-44-06-1933" ref-type="bibr">18</xref>,<xref rid="b19-ijo-44-06-1933" ref-type="bibr">19</xref>). The NM has been shown to have an inhibitory effect on inflammatory mediators as COX-2 in prior studies (<xref rid="b5-ijo-44-06-1933" ref-type="bibr">5</xref>,<xref rid="b20-ijo-44-06-1933" ref-type="bibr">20</xref>,<xref rid="b21-ijo-44-06-1933" ref-type="bibr">21</xref>).</p>
<p>Optimal ECM structure depends upon adequate supplies of ascorbic acid and the amino acids lysine and proline to ensure proper synthesis and hydroxylation of collagen fibers. In addition, lysine contributes to ECM stability as a natural inhibitor of plasmin-induced proteolysis (<xref rid="b4-ijo-44-06-1933" ref-type="bibr">4</xref>,<xref rid="b22-ijo-44-06-1933" ref-type="bibr">22</xref>). Manganese and copper are also essential for collagen formation. There is considerable documentation of the potency of green tea extract in modulating cancer cell growth, metastasis, angiogenesis, and other aspects of cancer progression (<xref rid="b23-ijo-44-06-1933" ref-type="bibr">23</xref>&#x02013;<xref rid="b27-ijo-44-06-1933" ref-type="bibr">27</xref>). N-acetyl cysteine and selenium have demonstrated inhibition of tumor cell MMP-9 and invasive activities, as well as migration of endothelial cells through ECM (<xref rid="b28-ijo-44-06-1933" ref-type="bibr">28</xref>&#x02013;<xref rid="b30-ijo-44-06-1933" ref-type="bibr">30</xref>). Ascorbic acid demonstrates cytotoxic and antimetastatic actions on malignant cell lines (<xref rid="b14-ijo-44-06-1933" ref-type="bibr">14</xref>,<xref rid="b31-ijo-44-06-1933" ref-type="bibr">31</xref>&#x02013;<xref rid="b35-ijo-44-06-1933" ref-type="bibr">35</xref>) and cancer patients have been found to have low levels of ascorbic acid (<xref rid="b36-ijo-44-06-1933" ref-type="bibr">36</xref>,<xref rid="b37-ijo-44-06-1933" ref-type="bibr">37</xref>). Low levels of arginine, a precursor of nitric oxide (NO), can limit the production of NO, which has been shown to predominantly act as an inducer of apoptosis (<xref rid="b38-ijo-44-06-1933" ref-type="bibr">38</xref>).</p>
<p>In conclusion, the results of the <italic>in vivo</italic> study of murine 4T1 cells injected into the mammary pads of Balb/C mice confirmed the validity of this model to study breast cancer metastasis since metastasis was observed in lung, liver, spleen, kidney and heart, as in human breast cancer. The present study also demonstrated significant suppression of tumor growth and metastasis to all of these organs with NM dietary supplementation, which indicates NM inhibition of metastasis is based on targeting common parameters as MMPs and the collagen barrier. Furthermore, the <italic>in vivo</italic> results were supported by <italic>in vitro</italic> findings of NM suppression of cell proliferation, secretion of MMP-2 and MMP-9, migration and Matrigel invasion by 4T1 cells. These results suggest that NM has therapeutic potential in treatment of breast cancer.</p></sec></body>
<back>
<ack>
<p>The tissues were processed by IDEXX Reference Laboratories Inc. and consulting pathologist Dr Alexander DePaoli, provided the histology slides and analysis. The research was funded by Dr Rath Health Foundation (Santa Clara, CA, USA), a non-profit organization.</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ijo-44-06-1933"><label>1.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>American Cancer Society</collab></person-group><article-title>Breast cancer: what are the key statistics about breast cancer?</article-title><comment><ext-link xlink:href="http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics" ext-link-type="uri">http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics</ext-link>). Accessed 10/9/13. Last Medical Review: 09/11/2013. Last Revised: 10/01/2013</comment></element-citation></ref>
<ref id="b2-ijo-44-06-1933"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Harvey</surname><given-names>HA</given-names></name><name><surname>Lipton</surname><given-names>A</given-names></name></person-group><article-title>Metastatic breast cancer: overview of treatment</article-title><source>Clin Orthop</source><volume>414</volume><issue>Suppl</issue><fpage>132</fpage><lpage>137</lpage><year>2003</year></element-citation></ref>
<ref id="b3-ijo-44-06-1933"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>IJ</given-names></name></person-group><article-title>Molecular biology of cancer: invasion and metastasis</article-title><source>Cancer: Principles and Practice of Oncology</source><edition>5th edition</edition><person-group person-group-type="editor"><name><surname>De Vita</surname><given-names>VT</given-names></name><name><surname>Hellman</surname><given-names>S</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><publisher-name>Lippincott-Raven</publisher-name><publisher-loc>Philadelphia, PA</publisher-loc><fpage>135</fpage><lpage>152</lpage><year>1997</year></element-citation></ref>
<ref id="b4-ijo-44-06-1933"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rath</surname><given-names>M</given-names></name><name><surname>Pauling</surname><given-names>L</given-names></name></person-group><article-title>Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs</article-title><source>Orthomolecular Med</source><volume>7</volume><fpage>17</fpage><lpage>23</lpage><year>1992</year></element-citation></ref>
<ref id="b5-ijo-44-06-1933"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niedzwiecki</surname><given-names>A</given-names></name><name><surname>Roomi</surname><given-names>MW</given-names></name><name><surname>Kalinovsky</surname><given-names>T</given-names></name><name><surname>Rath</surname><given-names>M</given-names></name></person-group><article-title>Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer</article-title><source>Cancer Metastasis Rev</source><volume>29</volume><fpage>529</fpage><lpage>543</lpage><year>2010</year></element-citation></ref>
<ref id="b6-ijo-44-06-1933"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bibby</surname><given-names>MC</given-names></name></person-group><article-title>Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages</article-title><source>Eur J Cancer</source><volume>40</volume><fpage>852</fpage><lpage>857</lpage><year>2004</year></element-citation></ref>
<ref id="b7-ijo-44-06-1933"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eccles</surname><given-names>SA</given-names></name><name><surname>Box</surname><given-names>G</given-names></name><name><surname>Court</surname><given-names>W</given-names></name><name><surname>Sandle</surname><given-names>J</given-names></name><name><surname>Dean</surname><given-names>CJ</given-names></name></person-group><article-title>Preclinical models for the evaluation of targeted therapies of metastatic disease</article-title><source>Cell Biophys</source><volume>24&#x02013;25</volume><fpage>279</fpage><lpage>291</lpage><year>1994</year></element-citation></ref>
<ref id="b8-ijo-44-06-1933"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>RM</given-names></name></person-group><article-title>Orthotopic metastatic mouse models for anti-cancer drug discovery and evaluation: a bridge to the clinic</article-title><source>Invest New Drugs</source><volume>17</volume><fpage>343</fpage><lpage>359</lpage><year>1999</year></element-citation></ref>
<ref id="b9-ijo-44-06-1933"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vernon</surname><given-names>E</given-names></name><name><surname>Bakewell</surname><given-names>SJ</given-names></name><name><surname>Chodash</surname><given-names>LA</given-names></name></person-group><article-title>Deciphering the molecular basis of breast cancer metastasis with mouse models</article-title><source>Rev Endocr Metab Disord</source><volume>8</volume><fpage>199</fpage><lpage>213</lpage><year>2007</year></element-citation></ref>
<ref id="b10-ijo-44-06-1933"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Aloy</surname><given-names>J</given-names></name><name><surname>Sahagian</surname><given-names>GG</given-names></name></person-group><article-title>Imagable 4T1 model for the study of late stage breast cancer</article-title><source>BMC Cancer</source><volume>8</volume><fpage>228</fpage><year>2008</year></element-citation></ref>
<ref id="b11-ijo-44-06-1933"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aslakson</surname><given-names>CJ</given-names></name><name><surname>Miller</surname><given-names>FR</given-names></name></person-group><article-title>Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor</article-title><source>Cancer Res</source><volume>52</volume><fpage>1399</fpage><lpage>1405</lpage><year>1992</year></element-citation></ref>
<ref id="b12-ijo-44-06-1933"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonfil</surname><given-names>RD</given-names></name><name><surname>Bustuabad</surname><given-names>OD</given-names></name><name><surname>Ruggiero</surname><given-names>RA</given-names></name><name><surname>Meiss</surname><given-names>RP</given-names></name><name><surname>Pasqualini</surname><given-names>CD</given-names></name></person-group><article-title>Tumor necrosis can facilitate the appearance of metastases</article-title><source>Clin Exp Metastasis</source><volume>6</volume><fpage>121</fpage><lpage>129</lpage><year>1988</year></element-citation></ref>
<ref id="b13-ijo-44-06-1933"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonfil</surname><given-names>RD</given-names></name><name><surname>Medina</surname><given-names>PA</given-names></name><name><surname>G&#x000F3;mez</surname><given-names>DE</given-names></name><name><surname>Far&#x000ED;as</surname><given-names>E</given-names></name><name><surname>Lazarowski</surname><given-names>A</given-names></name><name><surname>Lucero Gritti</surname><given-names>MF</given-names></name><name><surname>Meiss</surname><given-names>RP</given-names></name><name><surname>Bustuabad</surname><given-names>OD</given-names></name></person-group><article-title>Expression of gelatinase/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion</article-title><source>Clin Exp Metastasis</source><volume>10</volume><fpage>211</fpage><lpage>220</lpage><year>1992</year></element-citation></ref>
<ref id="b14-ijo-44-06-1933"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>J</given-names></name><name><surname>Roomi</surname><given-names>MW</given-names></name><name><surname>Ivanov</surname><given-names>V</given-names></name><name><surname>Kalinovsky</surname><given-names>T</given-names></name><name><surname>Niedzwiecki</surname><given-names>A</given-names></name><name><surname>Rath</surname><given-names>M</given-names></name></person-group><article-title>Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C deficient mice</article-title><source>Int J Oncol</source><volume>42</volume><fpage>55</fpage><lpage>64</lpage><year>2013</year></element-citation></ref>
<ref id="b15-ijo-44-06-1933"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmeier</surname><given-names>BE</given-names></name><name><surname>Nerlich</surname><given-names>AG</given-names></name><name><surname>Lichtinghagen</surname><given-names>R</given-names></name><name><surname>Sommerhoff</surname><given-names>CP</given-names></name></person-group><article-title>Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity</article-title><source>Anticancer Res</source><volume>6A</volume><fpage>3821</fpage><lpage>3828</lpage><year>2001</year></element-citation></ref>
<ref id="b16-ijo-44-06-1933"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellikainen</surname><given-names>JM</given-names></name><name><surname>Ropponen</surname><given-names>KM</given-names></name><name><surname>Kataja</surname><given-names>VV</given-names></name><name><surname>Kellokoski</surname><given-names>JK</given-names></name><name><surname>Eskelinen</surname><given-names>MJ</given-names></name><name><surname>Kosma</surname><given-names>VM</given-names></name></person-group><article-title>Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER-2, and prognosis</article-title><source>Clin Cancer Res</source><volume>10</volume><fpage>7621</fpage><lpage>7628</lpage><year>2004</year></element-citation></ref>
<ref id="b17-ijo-44-06-1933"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>EM</given-names></name><name><surname>Harmey</surname><given-names>JH</given-names></name><name><surname>O&#x00027;Grady</surname><given-names>T</given-names></name><name><surname>Foley</surname><given-names>D</given-names></name><name><surname>Roche-Nagle</surname><given-names>G</given-names></name><name><surname>Kay</surname><given-names>E</given-names></name><name><surname>Bouchier-Hayes</surname><given-names>DJ</given-names></name></person-group><article-title>Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer</article-title><source>Br J Cancer</source><volume>87</volume><fpage>231</fpage><lpage>237</lpage><year>2002</year></element-citation></ref>
<ref id="b18-ijo-44-06-1933"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denardo</surname><given-names>DG</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Coussans</surname><given-names>LM</given-names></name></person-group><article-title>Immune cells as mediators of solid tumor metastasis</article-title><source>Cancer Metastasis Rev</source><volume>27</volume><fpage>11</fpage><lpage>18</lpage><year>2008</year></element-citation></ref>
<ref id="b19-ijo-44-06-1933"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kempen</surname><given-names>LC</given-names></name><name><surname>de Visser</surname><given-names>KE</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group><article-title>Inflammation, proteases and cancer</article-title><source>Eur J Cancer</source><volume>42</volume><fpage>728</fpage><lpage>734</lpage><year>2006</year></element-citation></ref>
<ref id="b20-ijo-44-06-1933"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roomi</surname><given-names>MW</given-names></name><name><surname>Kalinovsky</surname><given-names>T</given-names></name><name><surname>Roomi</surname><given-names>NW</given-names></name><name><surname>Rath</surname><given-names>M</given-names></name><name><surname>Niedzwiecki</surname><given-names>A</given-names></name></person-group><article-title>Inhibition of growth and expression of inflammation mediators in human leukemic cell line</article-title><source>Exp Oncol</source><volume>35</volume><fpage>180</fpage><lpage>186</lpage><year>2013</year></element-citation></ref>
<ref id="b21-ijo-44-06-1933"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Roomi</surname><given-names>MW</given-names></name><name><surname>Kalinovsky</surname><given-names>T</given-names></name><name><surname>Niedzwiecki</surname><given-names>A</given-names></name><name><surname>Rath</surname><given-names>M</given-names></name></person-group><article-title>Pleiotropic effects of a micronutrient mixture on critical parameters of bladder cancer</article-title><source>Bladder Cancer Etymology, Diagnosis and Treatments</source><person-group person-group-type="editor"><name><surname>Nilsson</surname><given-names>WE</given-names></name></person-group><publisher-name>Nova Science Publishers, Inc.</publisher-name><publisher-loc>New York</publisher-loc><year>2009</year></element-citation></ref>
<ref id="b22-ijo-44-06-1933"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gurewich</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>JN</given-names></name></person-group><article-title>The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation</article-title><source>Biochem Biophys Acta</source><volume>1596</volume><fpage>182</fpage><lpage>192</lpage><year>2002</year></element-citation></ref>
<ref id="b23-ijo-44-06-1933"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valcic</surname><given-names>S</given-names></name><name><surname>Timmermann</surname><given-names>BN</given-names></name><name><surname>Alberts</surname><given-names>DS</given-names></name><name><surname>Wachter</surname><given-names>GA</given-names></name><name><surname>Krutzsch</surname><given-names>M</given-names></name><name><surname>Wymer</surname><given-names>J</given-names></name><name><surname>Guillen</surname><given-names>JM</given-names></name></person-group><article-title>Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines</article-title><source>Anticancer Drugs</source><volume>7</volume><fpage>461</fpage><lpage>468</lpage><year>1996</year></element-citation></ref>
<ref id="b24-ijo-44-06-1933"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhtar</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name></person-group><article-title>Tea polyphenols: prevention of cancer and optimizing health</article-title><source>Am J Clin Nutr</source><volume>71</volume><fpage>S1698</fpage><lpage>S1702</lpage><year>2000</year></element-citation></ref>
<ref id="b25-ijo-44-06-1933"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>GY</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Yurtow</surname><given-names>EJ</given-names></name><name><surname>Yang</surname><given-names>CS</given-names></name></person-group><article-title>Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols</article-title><source>Carcinogenesis</source><volume>19</volume><fpage>611</fpage><lpage>616</lpage><year>1998</year></element-citation></ref>
<ref id="b26-ijo-44-06-1933"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>S</given-names></name><name><surname>Fujiki</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Go</surname><given-names>H</given-names></name><name><surname>Miyado</surname><given-names>K</given-names></name><name><surname>Sadano</surname><given-names>H</given-names></name><name><surname>Shimikawa</surname><given-names>R</given-names></name></person-group><article-title>Effect of (&#x02212;) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines</article-title><source>Cancer Lett</source><volume>65</volume><fpage>51</fpage><lpage>54</lpage><year>1992</year></element-citation></ref>
<ref id="b27-ijo-44-06-1933"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>Y</given-names></name></person-group><source>Green tea: Health Benefits and Applications</source><publisher-name>Marcel Dekker</publisher-name><publisher-loc>New York, Basel</publisher-loc><year>2001</year></element-citation></ref>
<ref id="b28-ijo-44-06-1933"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>S</given-names></name><name><surname>Kageyama</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Kihara</surname><given-names>K</given-names></name><name><surname>Oshima</surname><given-names>H</given-names></name></person-group><article-title>Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells</article-title><source>Anticancer Res</source><volume>21</volume><fpage>213</fpage><lpage>219</lpage><year>2001</year></element-citation></ref>
<ref id="b29-ijo-44-06-1933"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morini</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Aluigi</surname><given-names>MG</given-names></name><name><surname>Noonan</surname><given-names>DM</given-names></name><name><surname>Masiello</surname><given-names>L</given-names></name><name><surname>De Floro</surname><given-names>S</given-names></name><name><surname>D&#x02019;Agostinin</surname><given-names>F</given-names></name><name><surname>Albini</surname><given-names>A</given-names></name><name><surname>Fassima</surname><given-names>G</given-names></name></person-group><article-title>The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis</article-title><source>Int J Biol Markers</source><volume>14</volume><fpage>268</fpage><lpage>271</lpage><year>1999</year></element-citation></ref>
<ref id="b30-ijo-44-06-1933"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>SO</given-names></name><name><surname>Kim</surname><given-names>MM</given-names></name><name><surname>Chung</surname><given-names>AS</given-names></name></person-group><article-title>Inhibitory effects of selenite on invasion of HT 1080 tumor cells</article-title><source>J Biol Chem</source><volume>276</volume><fpage>20085</fpage><lpage>20092</lpage><year>2001</year></element-citation></ref>
<ref id="b31-ijo-44-06-1933"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naidu</surname><given-names>KA</given-names></name><name><surname>Karl</surname><given-names>RC</given-names></name><name><surname>Coppola</surname><given-names>D</given-names></name></person-group><article-title>Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor</article-title><source>Dig Dis Sci</source><volume>48</volume><fpage>230</fpage><lpage>237</lpage><year>2003</year></element-citation></ref>
<ref id="b32-ijo-44-06-1933"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>HM</given-names></name><name><surname>Schorah</surname><given-names>CJ</given-names></name></person-group><article-title>Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance</article-title><source>Br J Cancer</source><volume>46</volume><fpage>354</fpage><lpage>367</lpage><year>1982</year></element-citation></ref>
<ref id="b33-ijo-44-06-1933"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maramag</surname><given-names>C</given-names></name><name><surname>Menon</surname><given-names>M</given-names></name><name><surname>Balaji</surname><given-names>KC</given-names></name><name><surname>Reddy</surname><given-names>PG</given-names></name><name><surname>Laxmanan</surname><given-names>S</given-names></name></person-group><article-title>Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis</article-title><source>Prostate</source><volume>32</volume><fpage>188</fpage><lpage>195</lpage><year>1997</year></element-citation></ref>
<ref id="b34-ijo-44-06-1933"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Yoon</surname><given-names>SS</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Hong</surname><given-names>SI</given-names></name><name><surname>Chung</surname><given-names>MH</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name></person-group><article-title>Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines</article-title><source>Anticancer Res</source><volume>8</volume><fpage>2487</fpage><lpage>2493</lpage><year>1998</year></element-citation></ref>
<ref id="b35-ijo-44-06-1933"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Espey</surname><given-names>MG</given-names></name><name><surname>Krishna</surname><given-names>MC</given-names></name><name><surname>Mitchell</surname><given-names>JB</given-names></name><name><surname>Corpe</surname><given-names>CP</given-names></name><name><surname>Buettner</surname><given-names>GR</given-names></name><name><surname>Shacter</surname><given-names>E</given-names></name><name><surname>Levine</surname><given-names>M</given-names></name></person-group><article-title>Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues</article-title><source>Proc Natl Acad Sci USA</source><volume>102</volume><fpage>13604</fpage><lpage>13609</lpage><year>2005</year></element-citation></ref>
<ref id="b36-ijo-44-06-1933"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunez</surname><given-names>C</given-names></name><name><surname>Ortiz de Apodaca</surname><given-names>Y</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name></person-group><article-title>Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin</article-title><source>Nutr Hosp</source><volume>10</volume><fpage>368</fpage><lpage>372</lpage><year>1995</year></element-citation></ref>
<ref id="b37-ijo-44-06-1933"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurbacher</surname><given-names>CM</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><name><surname>Kolster</surname><given-names>B</given-names></name><name><surname>Andreotti</surname><given-names>PE</given-names></name><name><surname>Krebs</surname><given-names>D</given-names></name><name><surname>Bruckner</surname><given-names>HW</given-names></name></person-group><article-title>Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro</article-title><source>Cancer Lett</source><volume>103</volume><fpage>183</fpage><lpage>189</lpage><year>1996</year></element-citation></ref>
<ref id="b38-ijo-44-06-1933"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>JP</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name></person-group><article-title>Nitric oxide synthase: role in the genesis of vascular disease</article-title><source>Annu Rev Med</source><volume>48</volume><fpage>489</fpage><lpage>509</lpage><year>1997</year></element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="f1-ijo-44-06-1933" position="float">
<label>Figure 1.</label>
<caption>
<p>Effect of NM 0.5&#x00025; supplementation on 4T1 tumor growth in Balb/C mice. (A) Mean tumor weight; (B) mean tumor burden (the asterisk indicates significance of p&#x0003C;0.05 with respect to control).</p></caption>
<graphic xlink:href="IJO-44-06-1933-g00.tif"/>
<graphic xlink:href="IJO-44-06-1933-g01.tif"/></fig>
<fig id="f2-ijo-44-06-1933" position="float">
<label>Figure 2.</label>
<caption>
<p>(A) Gross tumor images of control and NM 0.5&#x00025; group tumors; (B) mice from control group; (C) mice from NM 0.5&#x00025; group.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g02.tif"/>
<graphic xlink:href="IJO-44-06-1933-g03.tif"/>
<graphic xlink:href="IJO-44-06-1933-g04.tif"/></fig>
<fig id="f3-ijo-44-06-1933" position="float">
<label>Figure 3.</label>
<caption>
<p>Tumor histopathology. (A) Control tumor, &#x000D7;40; (B) control tumor, &#x000D7;200; (C) NM 0.5&#x00025; tumor, &#x000D7;40; (D) NM 0.5&#x00025; tumor, &#x000D7;200.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g05.tif"/>
<graphic xlink:href="IJO-44-06-1933-g06.tif"/>
<graphic xlink:href="IJO-44-06-1933-g07.tif"/>
<graphic xlink:href="IJO-44-06-1933-g08.tif"/></fig>
<fig id="f4-ijo-44-06-1933" position="float">
<label>Figure 4.</label>
<caption>
<p>Lung metastasis. (A) Mean number of colonies in lungs of control and NM 0.5&#x00025; group; (B) comparative weights of lungs in control and NM 0.5&#x00025; group (the asterisk indicates significance of p&#x0003D;0.0001 with respect to control).</p></caption>
<graphic xlink:href="IJO-44-06-1933-g09.tif"/>
<graphic xlink:href="IJO-44-06-1933-g10.tif"/></fig>
<fig id="f5-ijo-44-06-1933" position="float">
<label>Figure 5.</label>
<caption>
<p>Gross lung images of mice on control and NM supplemented diets.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g11.tif"/></fig>
<fig id="f6-ijo-44-06-1933" position="float">
<label>Figure 6.</label>
<caption>
<p>Lung histopathology. (A) Lung control, &#x000D7;40; (B) lung NM 0.5&#x00025;, &#x000D7;100.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g12.tif"/>
<graphic xlink:href="IJO-44-06-1933-g13.tif"/></fig>
<fig id="f7-ijo-44-06-1933" position="float">
<label>Figure 7.</label>
<caption>
<p>Mean weights of livers, kidneys, spleens and hearts in control and NM groups.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g14.tif"/></fig>
<fig id="f8-ijo-44-06-1933" position="float">
<label>Figure 8.</label>
<caption>
<p>Gross images of control group livers.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g15.tif"/></fig>
<fig id="f9-ijo-44-06-1933" position="float">
<label>Figure 9.</label>
<caption>
<p>Histopathology of livers. (A) Liver control, &#x000D7;100; (B) liver NM 0.5&#x00025;, &#x000D7;100.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g16.tif"/>
<graphic xlink:href="IJO-44-06-1933-g17.tif"/></fig>
<fig id="f10-ijo-44-06-1933" position="float">
<label>Figure 10.</label>
<caption>
<p>Gross images of control group kidneys.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g18.tif"/></fig>
<fig id="f11-ijo-44-06-1933" position="float">
<label>Figure 11.</label>
<caption>
<p>Histopathology of kidneys. (A) Kidney control, &#x000D7;100; (B) kidney NM 0.5&#x00025;, &#x000D7;100.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g19.tif"/>
<graphic xlink:href="IJO-44-06-1933-g20.tif"/></fig>
<fig id="f12-ijo-44-06-1933" position="float">
<label>Figure 12.</label>
<caption>
<p>Gross images of hearts.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g21.tif"/></fig>
<fig id="f13-ijo-44-06-1933" position="float">
<label>Figure 13.</label>
<caption>
<p>Histopathology of hearts. (A) Control heart, &#x000D7;40; (B) NM 0.5&#x00025; heart, &#x000D7;40.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g22.tif"/>
<graphic xlink:href="IJO-44-06-1933-g23.tif"/></fig>
<fig id="f14-ijo-44-06-1933" position="float">
<label>Figure 14.</label>
<caption>
<p>Gross images of control spleen.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g24.tif"/></fig>
<fig id="f15-ijo-44-06-1933" position="float">
<label>Figure 15.</label>
<caption>
<p>Histopathology of spleen. (A) Control spleen, &#x000D7;100; (B) NM spleen, &#x000D7;100.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g25.tif"/>
<graphic xlink:href="IJO-44-06-1933-g26.tif"/></fig>
<fig id="f16-ijo-44-06-1933" position="float">
<label>Figure 16.</label>
<caption>
<p>Effect of NM on 4T1 cell proliferation - MTT 24-h assay (the asterisk indicates significance of p&#x0003C;0.0001 with respect to control).</p></caption>
<graphic xlink:href="IJO-44-06-1933-g27.tif"/></fig>
<fig id="f17-ijo-44-06-1933" position="float">
<label>Figure 17.</label>
<caption>
<p>Effect of NM on MMP-2 and MMP-9 secretion by 4T1 cells: gelatinase zymography. (A) Untreated 4T1 cells; (B) PMA-treated 4T1 cells.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g28.tif"/></fig>
<fig id="f18-ijo-44-06-1933" position="float">
<label>Figure 18.</label>
<caption>
<p>Effect of NM on 4T1 cell migration: scratch test. (A) Pre-scratch; (B) control 24 h; (C) NM 50 <italic>&#x003BC;</italic>g/ml 24 h; (D) NM 100 <italic>&#x003BC;</italic>g/ml 24 h; (E) NM 250 <italic>&#x003BC;</italic>g/ml 24 h; (F) NM 500 <italic>&#x003BC;</italic>g/ml 24 h; (G) NM 1,000 <italic>&#x003BC;</italic>g/ml 24 h.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g29.tif"/>
<graphic xlink:href="IJO-44-06-1933-g30.tif"/>
<graphic xlink:href="IJO-44-06-1933-g31.tif"/>
<graphic xlink:href="IJO-44-06-1933-g32.tif"/>
<graphic xlink:href="IJO-44-06-1933-g33.tif"/>
<graphic xlink:href="IJO-44-06-1933-g34.tif"/>
<graphic xlink:href="IJO-44-06-1933-g35.tif"/></fig>
<fig id="f19-ijo-44-06-1933" position="float">
<label>Figure 19.</label>
<caption>
<p>Effect of NM on 4T1 cell invasion through Matrigel; photomicrographs. (A) Control; (B) NM 50 <italic>&#x003BC;</italic>g/ml; (C) NM 100 <italic>&#x003BC;</italic>g/ml; (D) NM 250 <italic>&#x003BC;</italic>g/ml.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g36.tif"/>
<graphic xlink:href="IJO-44-06-1933-g37.tif"/>
<graphic xlink:href="IJO-44-06-1933-g38.tif"/>
<graphic xlink:href="IJO-44-06-1933-g39.tif"/></fig>
<fig id="f20-ijo-44-06-1933" position="float">
<label>Figure 20.</label>
<caption>
<p>Effect of NM on 4T1 cell morphology: H&#x00026;E staining. (A) Control; (B) NM 50 <italic>&#x003BC;</italic>g/ml; (C) NM 100 <italic>&#x003BC;</italic>g/ml; (D) NM 250 <italic>&#x003BC;</italic>g/ml; (E) NM 500 <italic>&#x003BC;</italic>g/ml; (F) NM 1,000 <italic>&#x003BC;</italic>g/ml.</p></caption>
<graphic xlink:href="IJO-44-06-1933-g40.tif"/>
<graphic xlink:href="IJO-44-06-1933-g41.tif"/>
<graphic xlink:href="IJO-44-06-1933-g42.tif"/>
<graphic xlink:href="IJO-44-06-1933-g43.tif"/>
<graphic xlink:href="IJO-44-06-1933-g44.tif"/>
<graphic xlink:href="IJO-44-06-1933-g45.tif"/></fig></sec></back></article>
